Cargando…
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine
PURPOSE. To characterize folate receptor alpha (FRα) expression in archival and fresh biopsy tumor samples from relapsed ovarian cancer patients. METHODS. Patients with ovarian tumors amenable to biopsy were eligible to enroll. Eligibility included a minimum requirement of FRα positivity in archival...
Autores principales: | Martin, Lainie P., Konner, Jason A., Moore, Kathleen N., Seward, Shelly M., Matulonis, Ursula A., Perez, Raymond P., Su, Ying, Berkenblit, Anna, Ruiz-Soto, Rodrigo, Birrer, Michael J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893864/ https://www.ncbi.nlm.nih.gov/pubmed/28843653 http://dx.doi.org/10.1016/j.ygyno.2017.08.015 |
Ejemplares similares
-
Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
por: Gonzalez-Ochoa, Eduardo, et al.
Publicado: (2023) -
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
por: Matulonis, Ursula A., et al.
Publicado: (2023) -
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models()
por: Ponte, Jose F., et al.
Publicado: (2016) -
Serum folate receptor α (sFR) in ovarian cancer diagnosis and surveillance
por: Farran, Batoul, et al.
Publicado: (2019) -
Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications
por: Hulin-Curtis, Sarah L., et al.
Publicado: (2020)